PFE · Pfizer Inc.

Pfizer Inc PFE

Develops, manufactures, and markets prescription medicines and vaccines for humans.

Daily briefSeptember 1, 2026

Pfizer hits 52-week high on earnings beat and litigation settlement

+0.32% to $28.55 from $28.46

Pfizer stock touched a new 52-week high of $29.09 on Tuesday.
The company posted adjusted earnings per share of $0.77, above the $0.68 analyst consensus, on revenue of $15.03 billion versus $14.42 billion expected.
Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits alleging its Depo-Provera contraceptive was linked to intracranial meningioma, removing a product-liability overhang.
Pfizer raised its full-year 2026 adjusted EPS guidance to a range of $2.80 to $3.00.

Sources: The Cerbat Gem · MoneyCheck · Blockonomi

Daily briefAugust 4, 2026

+1.52% to $25.41 from $25.03

Q2 revenue was $15.03 billion, ahead of expectations, with adjusted EPS of 77 cents beating the 68-cent consensus.
Pfizer raised the low end of its full-year 2026 revenue guidance to $60.5-$62.5 billion, from a prior $59.5-$62.5 billion range.
The company cut its full-year Covid-product revenue outlook (Comirnaty and Paxlovid) to about $4 billion from roughly $5 billion previously.
Results included a $4.3 billion noncash impairment charge tied to disappointing late-stage trial results for cancer drug sigvotatug vedotin and the removal of revenue projections for sickle-cell drug Oxbryta.
Shares rose about 1.8% in premarket trading.

Sources: qz.com